Background {#Sec1}
==========

Telerobotic surgery has been introduced in the field of gynecology and contributed to great progress in surgical management. Since the introduction of radical hysterectomy using robots in patients with early-stage cervical cancer, robotic-assisted radical hysterectomy has been rapidly adopted in gynecologic oncology. Robotic-assisted radical hysterectomy yields a shorter surgical time, lesser blood loss, shorter hospital stay, faster recovery, less postoperative pain, and fewer complications than does traditional abdominal radical hysterectomy and laparoscopic-assisted radical hysterectomy \[[@CR1]--[@CR3]\]. Although there has been marked development in surgical techniques, there is no easy and fast method of predicting complications in minimally invasive surgeries. Predicting postoperative complications improves the quality of care by increasing patient satisfaction and reducing the readmission rate and medical resource wasting \[[@CR4]\].

In 1953, the neonatal Apgar score was introduced and has brought a considerable change the prediction of neonatal outcomes \[[@CR5]\]. Gawande et al. devised the surgical Apgar score (SAS) based on this concept and applied it to general or vascular surgery \[[@CR6]\]. The SAS, a 10-point scoring system, comprises 3 components: estimated blood loss (EBL), mean arterial pressure (MAP), and heart rate (HR) during surgery. The SAS ranges from 0 to 10; a low SAS indicates poor outcomes as in the neonatal Apgar score.

Since its introduction, the SAS has been validated for its usefulness in surgical fields, including urologic, head and neck, neurosurgical, orthopedic, transplant, and gastrointestinal surgeries \[[@CR7]--[@CR15]\]. It has also been used in gynecologic oncology. Low SASs (≤4) were reported as a strong predictor of postoperative complications after cytoreduction for advanced ovarian cancer \[[@CR16]\]. The SAS was applied to elderly patients who underwent non-laparoscopic surgery and was confirmed its usefulness \[[@CR17]\]. Low SASs were associated with morbidity but were unable to predict postoperative complications in patients undergoing hysterectomy for malignancy \[[@CR18]\]. This controversy exists in other studies. Most studies have reported that the SAS was useful in predicting postoperative complications; however, other studies could not confirm this association \[[@CR9], [@CR19], [@CR20]\]. All previous studies on the SAS have been conducted in laparotomy surgery; no study has used this on minimally invasive surgeries, which are currently replacing traditional surgical approaches. We sought to evaluate whether the SAS could predict perioperative complications in patients undergoing robotic-assisted radical hysterectomy for cervical cancer.

Methods {#Sec2}
=======

All patients with cervical cancer undergoing robotic radical surgery at our institution between January 2011 and May 2017 were included. All final diagnoses were confirmed by our gynecologic pathologists. Patients were excluded if they had incomplete medical records. Radical hysterectomy or trachelectomy (and/or bilateral pelvic lymph node dissection, paraaortic lymph node dissection, and/or bilateral salpingo-oophorectomy) was performed depending on the stage and fertility preservation of the patients. Data were retrieved from the patients' medical records (inpatient and outpatient, pathologic, anesthetic, and surgical records). We collected data on the patients' demographics, perioperative complications, and SAS.

Perioperative complications were defined as described by previous study and the Clavien-Dindo classification, and subdivided into intraoperative and postoperative complications \[[@CR1]\]. Postoperative complications included fever (\> 37.8 °C) for \> 24 h postoperatively, urinary distention, ileus, vault bleeding, readmission within 30 days after surgery, lymphedema, nerve palsy, wound dehiscence, fistula, and peritonitis. Intraoperative complications included transfusion within 72 h after surgery, large blood loss amount (≥300 mL), and organ injury.

The SAS was calculated from the EBL, lowest MAP, and lowest HR. Because the EBL of the SAS was set for open surgery, applying it to minimally invasive surgeries was difficult. Thus, we applied the modified SAS (MSAS) based on the lesser blood loss typical of robotic surgeries (Table [1](#Tab1){ref-type="table"}). The lowest HR and MAP were obtained from the anesthetic records. During surgery, the patients' vital signs were recorded on an anesthesia record every 5 min. The EBL was obtained from the surgical records. The surgical team (surgeon, nurse, and anesthesiologist) evaluated blood loss after surgery and recorded it on the surgical note. We also analyzed the risk-stratified MSAS in 3 subgroups: low (MSAS, 7--10), moderate (MSAS, 5--6), and high risks (MSAS, 0--4).Table 1Original SAS and MSAS0 points1 point2 points3 points4 pointsSAS EBL (mL)\> 1000601--1000101--600≤100\_ Lowest MAP (mmHg)\< 4040--5455--69≥70\_ Lowest HR (beats/min)\> 8576--8566--7555--65≤55MSAS EBL (mL)\> 300151--30051--150≤50\_ Lowest MAP (mmHg)\< 4040--5455--69≥70\_ Lowest HR (beats/min)\> 8576--8566--7555--65≤55*SAS* surgical Apgar score, *MSAS* modified surgical Apgar score, *EBL* estimated blood loss, *MAP* mean arterial pressure, *HR* heart rate

Clinical variables were compared using Student's t-test as appropriate for univariate analysis. Categorical variables were compared using Chi-square test and Fisher's exact test. Significantly associated variables were analyzed utilizing the linear-by-linear association test. Data were shown as means \[± standard deviations (SDs)\], medians (ranges), and numbers of patients (%), where applicable. For all statistical analyses, *p*-values \< 0.05 were considered statistically significant. Statistical analysis was performed using SPSS version 23.0 (Chicago, Illinois, USA).

Results {#Sec3}
=======

Between January 2011 and May 2017, 148 patients underwent robotic-assisted radical surgery for cervical cancer at our institution; 10 of them had incomplete medical records. Thus, a total of 138 patients were finally enrolled. Twenty-one patients (17.95%) underwent robotic-assisted radical trachelectomy, and 117 patients (82.05%) underwent RRH. In this cohort, 53 patients (38.4%) had a total of 67 perioperative complications; 27 patients (19.6%) had intraoperative complications; 38 patients (27.5%), postoperative complications; and 12 patients (8.7%), both. According to the Clavien-Dindo classification, 49 perioperative complications were classified under Grade I (73.1%); 13, under Grade II (19.4%); and 5, under Grade III (7.5%); 0, under both Grade IV and Grade V. Table [2](#Tab2){ref-type="table"} shows the perioperative complications details.Table 2The Clavien-Dindo classification and perioperative complications detailsNumberPercentClavien-Dindo classification^a^ Grade I4973.1 Grade II1319.4 Grade III57.5 Grade IV00 Grade V00Perioperative complications^b^ Intraoperative complications  Bleeding (≥300 mL)1611.59  Transfusion107.25  Bowel injury10.72  Bladder or ureter injury10.72 Postoperative complications  Fever for \> 24 h1712.32  Urinary distention64.35  Ileus32.17  Vault bleeding21.45  Readmission at \< 30 days21.45  Lymphedema21.45  Dysrhythmia21.45  Nerve palsy21.45  Wound dehiscence10.72  Fistula10.72  Peritonitis10.72^a^In relation to the total number of complications (*n* = 67)^b^In relation to the total number of patients (*n* = 138)

The patients' clinical characteristics and MSASs are summarized in Table [3](#Tab3){ref-type="table"}. The mean age and body mass index (BMI) were not significantly different between the groups. Neoadjuvant chemotherapy (NAC) before surgery \[4 (4.7%) vs. 3 (5.8%); *p* = 0.77\] and surgical radicality were also not significantly different (*p* = 0.47). Perioperative complications were significantly associated with surgical time (*p* = 0.026). The SAS was also not significantly different; however, the MSAS was associated with perioperative complications (*p* = 0.047).Table 3Patients' clinical characteristics and MSASComplication*P-*valueNo (*n* = 85)Yes (*n* = 53)Age (years)44.1 (±10.1)43.1 (±9.8)0.51BMI (kg/m^2^)22.9 (±3.0)22.9 (±3.3)0.98Underlying disease (*n*)17 (20.0)7 (13.2)0.31Previous pelvic surgery (*n*)35 (41.2)18 (33.7)0.40Surgical time (min)190.0 (±70.9)221.0 (±90.0)0.026Preoperative Hb (g/dL)13.0 (±1.20)12.6 (±1.3)0.10Postoperative Hb (g/dL)12.8 (±1.3)11.0 (±1.3)0.27NAC (*n*)4 (4.7)3 (5.8)0.77Surgical procedure (*n*)0.47 Radical trachelectomy (±BPLD and PALND)12 (14.1)9 (17.0) Radical hysterectomy (±BPLD, PALND, and BSO)73 (85.9)44 (83.0)SAS7.4 (±1.1)7.1 (±1.3)0.27MSAS7.0 (±1.2)6.5 (±1.8)0.047*MSAS* modified surgical Apgar score, *BMI* body mass index, *Hb* hemoglobulin, *NAC* neoadjuvant chemotherapy, *BPLD* bilateral pelvic lymph node dissection, *PALND* paraaortic lymph node dissection, *BSO* bilateral salpingo-oophorectomy, *SAS* surgical Apgar scoreData are presented as means (± standard deviations) or as numbers of patients (%)

Table [4](#Tab4){ref-type="table"} shows the correlation of the complications with a low MSAS (MSAS, ≤6). In the total cohort, 52 patients (36.7%) had an MSAS of ≤6, and 86 patients (62.3%) had an MSAS of \> 6. We did not find an association between a low MSAS and age, BMI, underlying disease, previous pelvic surgery, NAC, and extensive surgical procedures. The preoperative hemoglobulin level was higher in the low MSAS group than in the high MSAS group \[mean (SD): 13.2 (±1.2) vs. 12.6 (±1.2); *p* = 0.01\]. The low MSAS group had significantly more complications \[40 (76.9%), *p* = 0.01\]. The intraoperative complications were more correlated with a low MSAS than the postoperative complications \[1 (1.2%) vs. 21 (40.4%); *p* \< 0.001, 13 (15.1%) vs. 25 (48.1%); *p* = 0.29, respectively\].Table 4Characteristics of the patients with low MSASsMSAS of \> 6 (*n* = 86)MSAS of ≤6 (*n* = 52)*P-*valueAge (years)43.1 (±9.9)44.7 (±10.1)0.37BMI (kg/m^2^)22.7 (±2.9)23.3 (±3.8)0.27Underlying disease (*n*)15 (17.4)9 (17.3)0.98Previous pelvic surgery (*n*)36 (41.9)17 (32.7)0.29NAC (*n*)4 (4.7)3 (5.8)0.77Radicality of surgery0.33Preoperative Hb (g/dL)12.6 (±1.2)13.2 (±1.2)0.012Perioperative complications (*n*)13 (15.1)40 (76.9)0.01Intraoperative complications (*n*)1 (1.2)26 (50)\< 0.001Postoperative complications (*n*)13 (15.1)25 (48.1)0.29*MSAS* modified surgical Apgar score, *BMI* body mass index, *NAC* neoadjuvant chemotherapy, *Hb* hemoglobulinData are provided as means (± standard deviations) or as numbers of patients (%)

In the low MSAS group, perioperative complications occurred in 40 (76.9%) patients; intraoperative complications in 26 (50%) patients; and postoperative complications in 25 (48.1%) patients. Table [5](#Tab5){ref-type="table"} shows the association between a low MSAS and operative complications; a low MSAS was not significantly associated with perioperative \[odds ratio (OR), 1.43; *p* = 0.36\] and postoperative complications (OR, 0.711; *p* = 0.4). However, a low MSAS was a predictor for intraoperative complications (OR, 3.57; 95% confidence interval: 1.0--12.7; *p* = 0.039) (Table [5](#Tab5){ref-type="table"}).Table 5Low MSASs (≤6) as a predictor for intraoperative complicationsOdds ratio95% CI*P-*valueFor perioperative complications1.430.7--3.1NSFor intraoperative complications3.5701.0--12.70.039For postoperative complications0.7110.3--1.6NS*NS* not significant, *CI* confidence interval

The linear-by-linear association test results for the perioperative and intraoperative complications with the risk-stratified MSASs are described in Fig. [1](#Fig1){ref-type="fig"}. The number of patients with perioperative complications was 7/15 (46.7%) in the low-risk group, 32/90 (35.6%) in the moderate-risk group, and 14/33 (42.4%) in the high-risk group. Among the patients with intraoperative complications, 0/15 (0%) were included in the low-risk group; 15/90 (16.7%) in the moderate-risk group; and 10/33 (30.3%) in the high-risk group. We could not confirm the significance of the increased prevalence of perioperative complications with the decreased MSAS (*p* = 0.98). However, the intraoperative complications significantly increased as the MSAS decreased (*p* = 0.01). The patients with increasing risk-stratified MSASs had a higher incidence of intraoperative complications.Fig. 1Linear-by-linear association test results of the perioperative and intraoperative complications with the risk-stratified MSAS. (**a**) Association between perioperative complications and risk-stratified MSAS; (**b**) association between intraoperative complications and risk-stratified MSAS. The patients with increasing risk-stratified MSASs have a higher incidence of intraoperative complications (**b**) (*p* = 0.01). However, this association was not found in the perioperative complications (**a**) (*p* = 0.98). MSAS, modified surgical Apgar score

Discussion {#Sec4}
==========

The current study showed that a low MSAS could predict perioperative complications in patients undergoing robotic-assisted radical hysterectomy. This supports the findings of previous studies that validated the usefulness of the SAS in predicting perioperative complications after major surgeries \[[@CR16], [@CR17]\]. The EBL scale in the SAS was slightly modified account for the lesser blood loss in robotic-assisted surgeries. A previous study also employed the modified EBL scale because of the larger blood loss and showed that the SAS could predict major postoperative complications and death \[[@CR7]\]. The difference between the current and previous studies is that most of the latter defined low SASs as ≤4; conversely, we defined it as ≤6 \[[@CR17]\]. We thought that the lesser blood loss, which is the strength of robotic-assisted radical hysterectomy, had influenced our results. Furthermore, our low MSAS definition reflects the risk assessment system of the Apgar score better, which is the basis of the SAS.

One study reported hospital readmissions within 30 days after discharge in 13.2% of 2455 patients in gynecologic oncology. Among them, 87% had gynecologic malignancies and 22.2% had cervical cancer \[[@CR4]\]. These unplanned readmissions are more costly than planned hospitalizations and yield lower medical care quality. Therefore, clinicians strive to predict postoperative complications using preoperative and intraoperative assessment tools, such as the American Society of Anesthesiologists Physical Status Classification System (ASA classification) \[[@CR21]\], Acute Physiology and Chronic Health Evaluation (APACHE) \[[@CR22]\], and Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM) \[[@CR23]\]. However, the ASA classification only reflects the patients' preoperative physical status and therefore does not reflect the patients' intraoperative conditions due to unexpected complications during surgery. Because of the complicated scoring system, the APACHE and POSSUM are not widely used in clinical practice for postoperative risk prediction \[[@CR18], [@CR24]\]. Complexity of surgical procedures, elevated serum glutamic oxaloacetic transaminase levels, higher ASA scores, and obesity were reported as risk factors for adverse events in gynecological cancer surgery \[[@CR16], [@CR25]\]. However, most patients with cervical cancer who can be treated surgically have no preoperative underlying diseases and do not have these preoperative risk factors. Therefore, intraoperative patient assessment is an important factor for predicting postoperative complications. For these reasons, surgeons need a useful tool to evaluate the patients' condition during urgent surgeries so that patients can receive appropriate postoperative care.

The SAS could be easily applied in clinical practice because it is a simple and intuitive scoring system. This scoring system assesses intraoperative management using only 3 objective factors (i.e., EBL, lowest HR, and lowest MAP during surgery); the lower the score, the higher the postoperative complication risk. The SAS is easy to calculate, interpret, and apply. Because of these attractive strengths, many researchers have been working on the clinical application of this new risk assessment tool to predict postoperative complications. The original study was conducted on patients who underwent colectomy, and the subsequent validation studies were conducted on large samples in other surgical fields. The SAS was applied to 4119 general and vascular surgery patients and demonstrated its usefulness \[[@CR26]\]. The past study confirmed the validity of the SAS in patients from a low-income country who underwent laparotomy \[[@CR27]\]. Recently, a new surgical scoring system has been proposed that combines intraoperative assessment of the SAS and preoperative assessment of the ASA score to predict postoperative mortality \[[@CR28], [@CR29]\]. Immediate recognition of postoperative complications leads to careful postoperative management, prevents postoperative complications, and improves patient outcome \[[@CR30]\].

Because the SAS reflects the intraoperative management status, low MSASs have a higher correlation with intraoperative complications. The patients with lower MSASs had a higher incidence of intraoperative complications. The previous study defined perioperative complications as blood transfusion after surgery and a large blood loss amount during surgery \[[@CR16]\]. We classified perioperative complications into intraoperative and postoperative complications and defined intraoperative complications as blood transfusion, a large blood loss amount, and organ injury.

One of the interesting findings of our study is that only 1 patient received transfusion among the 16 patients with an EBL amount of ≥300 mL. Postoperative transfusion was associated with lower MSASs rather than was absolute blood loss amount. Three pillars of transfusion in surgical patients were reported: detection and treatment of preoperative anemia; reduction of perioperative blood loss; and harnessing and optimizing the patient-specific physiological reserve of anemia \[[@CR31], [@CR32]\]. In addition to these 3 factors, our results showed that proper intraoperative management is also important for transfusion of surgical patients.

Our study has some limitations. First, this was a retrospective study conducted at a single tertiary academic center, and data were collected only from patients with cervical cancer undergoing robotic surgery. Second, the HR and blood pressure were recorded every 5 min in anesthesia records. Not all values were recorded during surgery; however, according to the monitoring guideline for safe anesthesia, vital signs were measured at least every 5 min or more often, if necessary, so that blood pressure and HR can be accurately assessed \[[@CR17], [@CR33]\]. Finally, our results were derived from a single disease and single surgical procedure, with similar surgical radicalities.

Despite these limitations, to the best our knowledge, this is the first study to investigate the MSAS in patients undergoing robotic-assisted radical hysterectomy. Preoperative and intraoperative risk assessments are important for surgeons to provide adequate postoperative care for patients. The 3 parameters could be useful for intraoperative risk assessment in minimally invasive surgeries. For the MSAS to be generally accepted, further prospective studies should be performed in various institutions and on various diseases and other minimally invasive surgeries.

Conclusions {#Sec5}
===========

This study was consistent the concept that the intuitive and simple MSAS might be more useful in predicting intraoperative complications than in predicting postoperative complications in minimally invasive surgeries, such as robotic-assisted radical hysterectomy for cervical cancer.
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